Analysis of nabumetone in human plasma by HPLC. Application to single dose pharmacokinetic studies

被引：22

作者：

Kobylinska, K ^{[1
]}

Barlinska, M ^{[1
]}

Kobylinska, M ^{[1
]}

机构：

[1] Pharmaceut Res Inst, Dept Pharmacol, PL-01793 Warsaw, Poland

来源：

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | 2003年 / 32卷 / 02期

关键词：

nabumetone; NSAID; HPLC; human plasma; fluorescence detection; pharmacokinetics;

D O I：

10.1016/S0731-7085(03)00078-5

中图分类号：

O65 [分析化学];

学科分类号：

070302 ; 081704 ;

摘要：

A simple and sensitive high performance liquid chromatography method for the determination of nabumetone in human plasma is described. The procedure involves liquid-liquid extraction with ethyl acetate and reversed-phase chromatography with fluorimetric detection (excitation 230 run, emission 356 nm). The chromatographic conditions and the extraction procedure gave a clean chromatogram for the compound. The limit of quantitation was established as 0.313 ng/ml and the calibration curve was linear up to 20 ng/ml. The within-day and between-day relative standard deviations were less than 10% and the accuracy of the assay was in the range of 99-104%. The suitability of the method is shown for pharmacokinetic studies. (C) 2003 Elsevier Science B.V. All rights reserved.

引用

页码：323 / +

页数：65

共 13 条

[1] Determination of nabumetone and its major metabolite in plasma and tablet formulations by reverse-phase HPLC [J].

AlMomani, IF .

ANALYTICAL LETTERS, 1997, 30 (14) :2485-2492

[2] Clinical pharmacokinetics of nabumetone - The dawn of selective cyclo-oxygenase-2 inhibition? [J].

Davies, NM .

CLINICAL PHARMACOKINETICS, 1997, 33 (06) :403-416

[3] Extractionless determination of 6-methoxy-2-naphthylacetic acid, a major metabolite of nabumetone, in human plasma by high-performance liquid chromatography [J].

de Jager, AD ;

Hundt, HKL ;

Hundt, AF ;

Swart, KJ ;

Knight, M ;

Roberts, J .

JOURNAL OF CHROMATOGRAPHY B, 2000, 740 (02) :247-251

[4] NABUMETONE - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN RHEUMATIC DISEASES [J].

FRIEDEL, HA ;

TODD, PA .

DRUGS, 1988, 35 (05) :504-524

[5] NABUMETONE - A REAPPRAISAL OF ITS PHARMACOLOGY AND THERAPEUTIC USE IN RHEUMATIC DISEASES [J].

FRIEDEL, HA ;

LANGTRY, HD ;

BUCKLEY, MM .

DRUGS, 1993, 45 (01) :131-156

[6] METABOLISM OF NABUMETONE (BRL-14777) BY VARIOUS SPECIES INCLUDING MAN [J].

HADDOCK, RE ;

JEFFERY, DJ ;

LLOYD, JA ;

THAWLEY, AR .

XENOBIOTICA, 1984, 14 (04) :327-337

[7]

HYNECK ML, 1989, J RHEUMATOL S36, V19, P299

[8] A PHARMACOKINETIC STUDY OF THE ACTIVE METABOLITE OF NABUMETONE IN YOUNG HEALTHY-SUBJECTS AND OLDER ARTHRITIS PATIENTS [J].

KENDALL, MJ ;

CHELLINGSWORTH, MC ;

JUBB, R ;

THAWLEY, AR ;

UNDRE, NA ;

KILL, DC .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (03) :299-305

[9] PENETRATION OF THE ACTIVE METABOLITE OF NABUMETONE INTO SYNOVIAL-FLUID AND ADHERENT TISSUE OF PATIENTS UNDERGOING KNEE-JOINT SURGERY [J].

MIEHLKE, RK ;

SCHNEIDER, S ;

SORGEL, F ;

MUTH, P ;

HENSCHKE, F ;

GIERSCH, KH ;

MUNZEL, P .

DRUGS, 1990, 40 :57-61

[10] Simultaneous analysis of naproxen, nabumetone and its major metabolite 6-methoxy-2-naphthylacetic acid in pharmaceuticals and human urine by high-performance liquid chromatography [J].

Mikami, E ;

Goto, T ;

Ohno, T ;

Matsumoto, H ;

Nishida, M .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 23 (05) :917-925

← 1 2 →